Esperion Therapeutics (ESPR) CEO Koenig Sells $169K of Stock

On June 17, 2026, Sheldon Koenig, the President and CEO of Esperion Therapeutics, Inc. (NasdaqGM: ESPR), sold 53,588 shares of the company. The shares were sold at an average price of $3.16, totaling approximately $169,338. This transaction was not part of a pre-arranged trading plan.

Insider Buying and Selling at Esperion Therapeutics, Inc.

In addition to Sheldon Koenig's sale, other insiders were active as well. Benjamin Halladay, the Chief Financial Officer, sold 10,773 shares on the same day, also at $3.16 per share. Benjamin Looker, the Chief Legal Officer, sold 11,824 shares at the same price. Earlier, on May 28, 2026, insiders Seth Fischer, John Craig Thompson, and Robert Hoffman each purchased 79,873 shares, though the transaction price was not disclosed.

Other Institutional Activity in Esperion Therapeutics

Several institutional investors adjusted their positions in Esperion Therapeutics. BlackRock, Inc. increased its holdings by 170,226 shares, ending with 17,852,427 shares valued at about $48.9 million. Wasatch Advisors LP significantly boosted its stake by 6,323,138 shares, bringing its total to 15,768,897 shares worth approximately $43.2 million. On the other hand, Two Seas Capital LP reduced its position by 507,688 shares, holding 11,394,833 shares valued at $31.2 million. OrbiMed Advisors LLC added 4,604,802 shares, totaling 10,570,300 shares valued at $28.9 million, while Vanguard Capital Management LLC initiated a new position with 10,433,760 shares worth about $28.6 million.

Esperion Therapeutics Stock Snapshot

Shares of Esperion Therapeutics traded near $3.15. The company has a market capitalization of approximately $811.7 million and a forward P/E ratio of 10.79. The stock's beta is 1.067, indicating moderate volatility. Over the past year, the stock has ranged from a low of $0.95 to a high of $4.18. Its 50-day moving average is $2.78, and the 200-day moving average is $3.02. The company holds a current ratio of 1.53 and a quick ratio of 0.961.

Recent Earnings

Esperion Therapeutics reported revenue of $418.2 million, with a revenue growth rate of 23.2%. Despite this growth, the company has a negative net margin of -1.775%. The next earnings report is scheduled for August 4, 2026.

Analysts Set New Price Targets

On May 1, 2026, HC Wainwright & Co. downgraded Esperion Therapeutics to a "hold" rating, setting a price target of $3.16. Citizens and Needham both maintained their "buy" ratings with targets of $5.00, while Piper Sandler initiated coverage with a "buy" rating and a $9.00 target. The consensus target price among analysts is $3.19.

About Esperion Therapeutics

Esperion Therapeutics, Inc. is a biopharmaceutical company based in Ann Arbor, Michigan. It focuses on developing and commercializing medicines to treat patients with high levels of low-density lipoprotein cholesterol (LDL-C) in the U.S. Its products include NEXLETOL and NEXLIZET tablets, which are non-statin options for managing primary hyperlipidemia. The company collaborates with global partners like Daiichi Sankyo and Otsuka Pharmaceutical.

Bottom Line

Sheldon Koenig's recent sale of shares in Esperion Therapeutics is a notable insider transaction. The company, specializing in cholesterol-lowering drugs, has seen varied institutional activity, with some funds increasing and others decreasing their stakes. Investors will be watching closely for the next earnings report in August and any further adjustments in analyst ratings.